Spevatamig (PT886) for Advanced Gastric, Pancreatic, or Biliary Tract Cancers
This study is testing a new drug called Spevatamig (PT886) for advanced gastric (stomach), gastroesophageal junction (where the esophagus meets the stomach), pancreatic, or biliary tract (bile duct) cancers. Spevatamig (PT886) is a bispecific antibody, meaning it targets two specific proteins (Claudin 18.2 and CD47) on cancer cells. You might receive Spevatamig (PT886) alone or in combination with chemotherapy drugs like Paclitaxel, Gemcitabine, and Abraxane, or with an immunotherapy drug called KEYTRUDA® (pembrolizumab). The main goals are to see how safe Spevatamig (PT886) is, how well you tolerate it, and if it can shrink tumors. This study is open to adults aged 18 and older who have measurable disease and have been previously treated for their cancer. The study plans to enroll 258 participants.
- Study design
- This is a Phase 1/2, open-label study, meaning both you and your doctors will know which treatment you are receiving. It involves different groups to test Spevatamig (PT886) alone and in various combinations.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety, tolerability, and anti-tumor activity will be evaluated through study completion, which is an average of 2 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
At a glance
Conditions
NCT05482893
Where you'd take part
This study runs at 11 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, Californiano site contact published
Recruiting
Duke Cancer Center
Durham, North Carolinano site contact published
Recruiting
MD Anderson Cancer Center, GI Medical Oncology Dept
Houston, Texasno site contact published
Recruiting
NEXT Oncology
Fairfax, Virginiano site contact published
Recruiting
Norton Cancer Institute
Louisville, Kentuckyno site contact published
Recruiting
Sarah Cannon Research Institute (SCRI)
Denver, Coloradono site contact published
Recruiting
University of Iowa
Iowa City, Iowano site contact published
Recruiting
University of Pittsburgh Medical Center (UPMC)
Pittsburgh, Pennsylvaniano site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To evaluate the safety and tolerability of Spevatamig (PT886) as monotherapy and in each individual combination substudy.Through study completion, an average of 2 years
- To evaluate anti-tumor activity of PT886 as assessed by ORR, in Spevatamig (PT886) monotherapy and in each combination substudy.Through study completion.
- To determine the recommended dose for expansion of Spevatamig (PT886) monotherapy.Through study completion.